Recurrent pregnancy-induced diabetes insipidus in a woman with hemochromatosis.
Diabetes insipidus is a rare disorder in pregnant women, predating pregnancy or appearing for the first time during gestation. In pregnancy it usually affects women with HELLP syndrome or acute fatty liver of pregnancy and results from the reduced hepatic degradation of placental vasopressinase leading to its increased activity. Although infiltrative diseases have been found to cause diabetes insipidus in non-pregnant population, very few studies showed that these disorders may manifest for the first time during gestation. We describe here the case of transient diabetes insipidus in two subsequent pregnancies of a female with hemochromatosis. The first symptoms of this disease appeared for the first time at the beginning of the third trimester of her second pregnancy, and diagnosis was established on the basis of typical clinical presentation, confirmed by a water deprivation test. Diabetes insipidus resulted from the increased activity of vasopressinase, caused by hemochromatosis-induced liver dysfunction, the presence of which was confirmed between the pregnancies by liver biopsy and identification of the HFE gene mutation. Subsequent desferrioxamine treatment resulted in a less severe clinical course of diabetes insipidus in the last patient's pregnancy. In both pregnancies, the patient was successfully treated with oral desmopressin, which is resistant to degradation by placental vasopressinase. Although unrecognized pituitary disorders may pose a serious health problem to the mother and fetus, hemochromatosis-induced diabetes insipidus, as the case of our patient demonstrates, if effectively diagnosed and treated, cannot be regarded as a contraindication for pregnancy.
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland. r.krysiak@interia.pl
Robert
R
Krysiak
Iwona
I
Kobielusz-Gembala
Boguslaw
B
Okopien
D000328:Adult; D001707:Biopsy, Needle; D010122:Cystinyl Aminopeptidase / Q000378:metabolism; D003676:Deferoxamine / Q000627:therapeutic use; D003919:Diabetes Insipidus / Q000209:etiology* / Q000517:prevention & control; D005260:Female; D006432:Hemochromatosis / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I / Q000235:genetics; D006801:Humans; D008107:Liver Diseases / Q000209:etiology / Q000473:pathology; D008565:Membrane Proteins / Q000235:genetics; D009154:Mutation; D011247:Pregnancy; D011248:Pregnancy Complications / Q000209:etiology*; D012008:Recurrence
C103673:HFE protein, human; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D010122:Cystinyl Aminopeptidase; D003676:Deferoxamine